Navigation Links
Small molecule dervived from Rb2/p130 could act as cancer therapeutic

A small molecule derived from the spacer domain of the tumor-suppressor gene Rb2/p130 has demonstrated the ability to inhibit tumor growth in vivo and could be developed into an anti-cancer therapeutic, according to researchers at Temple University's Sbarro Institute for Cancer Research and Molecular Medicine.

The researchers reported their findings, "A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo," in the March 22 issue of the journal Oncogene (http://www.nature.com/onc). Rb2/p130 was discovered in the early 1990s by Antonio Giordano, director of the Sbarro Institute (http://www.shro.org) and the Center for Biotechnology in Temple's College of Science and Technology, who headed the study.

The researchers discovered that within Rb2/p130's spacer domain--a sequence of 212 amino acids located in the pocket or middle section of the gene--was a small portion that resembled an amino-acidic sequence contained in the protein p21, which acts as a cdk (cyclin dependent kinase) inhibitor. Cdks play a critical role in cell cycle regulation.

"What we tested was the ability of the Rb2/p130 spacer region to inhibit the kinase activity of cdk2, which is the same kinase p21 inhibits," said Giordano, one of the study's lead authors. "And to our surprise, it happened." The researchers then set about trying to reduce the spacer domain's 212 amino acids down to the smallest sequence that would still produce the same functionality as p21, explained Giordano.

"We thought we could narrow down the spacer region that contains the protein-like motif to a small portion that could be delivered as a small molecule or peptide," Giordano said.

They discovered a 39 amino-acid-long sequence, which they named Spa310. The molecule that was synthetically produced in the laboratory was introduced into mice that had been injected with tumor cells.

"Tumor growth was inhibited and the tumors began to reduce in size until they disappeared," Giordano said.

Giordano said because of the intrinsic nature of the compound, it can be easily reproduced as a biological drug in large quantities and does not require potentially dangerous means of delivery like viruses, as do most gene therapies; therefore Spa310 has a good chance to succeed as an anti-cancer therapy. For these reasons, he believes it may be easier to get approval for clinical trials.

"Fifteen years after discovering Rb2/p130, our research and hard work has led us to the discovery of this small molecule, which is a step forward in cancer research and a big step toward a cancer treatment," he said.


'"/>

Source:Temple University


Related biology news :

1. Small species back-up giant marsupial climate change extinction claim
2. Small worm yields big clue on muscle receptor action
3. Small molecule inhibitor of cholera discovered
4. Small molecule interactions were central to the origin of life
5. Small, smaller, smallest -- The plight of the vaquita
6. Smallpox outbreak: How long would it take for vaccines to protect people? Would it work?
7. Chemists create Superbowl molecule; May lead to better health
8. Key molecule in plant photo-protection identified
9. Inflammatory molecules released by pollen trigger allergies
10. Researchers discover molecule that causes secondary stroke
11. Yale researchers identify molecule for detecting parasitic infection in humans
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/4/2017)... 2017  For the thousands of attendees at this year,s International Consumer ... health and biometric measurement devices and services, will be featuring its new ... in A&D Medical,s special CES Exhibit Suite , the new upper ... the company,s WellnessConnected product platform.  ... ...
(Date:12/20/2016)... The rising popularity of mobility services ... stoking significant interest in keyless access systems. Following ... energy (BLE), biometrics and near-field communication (NFC) are ... wireless technologies in the automotive industry. This evolution ... systems opens the market to specialist companies such ...
(Date:12/16/2016)... , Dec. 16, 2016 The global wearable medical ... 12.14 billion by 2021 from USD 5.31 billion in 2016, at ... ... mainly driven by technological advancements in medical devices, launch of a ... preference for wireless connectivity among healthcare providers, and increasing focus on ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... -- Market Research Future has a half cooked research report on Global ... rapidly and expected to reach USD 450 Million by the end ... ... been assessed as a swiftly growing market and expected that the ... future. There has been a tremendous growth in the prevalence of ...
(Date:1/19/2017)... Switzerland (PRWEB) , ... January ... ... provider of advanced software solutions for pharmaceutical research and development (R&D), today ... expertise in omic data analysis and interpretation for the rapidly evolving field ...
(Date:1/19/2017)... -- AquaBounty Technologies, Inc. (AIM: ABTU; NASDAQ: AQB), a ... a majority-owned subsidiary of Intrexon Corporation (NYSE: ... of its common shares on the NASDAQ Stock Market ... "AquaBounty,s listing on NASDAQ represents an important milestone for ... U.S. markets as we advance plans for commercial production ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... spanning the full spectrum of drug and device development, and Prism Clinical ... companies and clinicians, today announced Verified Clinical Trials (VCT) has been ...
Breaking Biology Technology: